戻る Agenda
Session 4 Track C: Personalized Medicine
Session Chair(s)
Karen Feltmate
President
Redstone Health Group, Inc., Canada
Session 4 Track C: Personalized Medicine
Learning Objective : 1) Understand the latest technological advancements in personalized medicine technology 2) Evaluate cost/benefit drivers for patient populations 3) Identify existing approved biomarkers and the implications of biomarker regulatory approval on product commercialization 4) Describe reimbursement considerations for personalized medicine based technologies in the health care arena
Speaker(s)
Session Co-Chair
Laura Durno, MS, MSc
Biologics and Genetic Therapies Directorate, Health Canada, Canada
Acting Chief, Viral Vaccines Division
The Keys to a Successful Personalized Medicine Strategy
Stephen F. Amato, PhD, RAC
Cardinal Health Regulatory Sciences, United States
Managing Director of East Coast Operations
Speaker
George Wyatt
Wyatt Health Management, Canada
Managing Director
Speaker
Katherine M. Soltys, MD
Health Canada, Canada
Director, Office of Clinical Trials, Pharmaceutical Drug Directorate